A 12 Weeks, Randomized, Double-blind, Multi-centers, Phase III Study to Evaluate the Efficacy and Safety of Shinbaro Capsule Compared With Celebrex Capsule in Patients With Osteoarthritis of Knee.

Trial Profile

A 12 Weeks, Randomized, Double-blind, Multi-centers, Phase III Study to Evaluate the Efficacy and Safety of Shinbaro Capsule Compared With Celebrex Capsule in Patients With Osteoarthritis of Knee.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs GCSB 5 (Primary) ; Celecoxib
  • Indications Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors GC Pharma; Green Cross
  • Most Recent Events

    • 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
    • 29 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top